Skip to content


  • Research
  • Open Access

Altered inflammatory responsiveness in serotonin transporter mutant rats

  • 1, 2,
  • 3,
  • 1,
  • 1,
  • 1, 4,
  • 1, 4 and
  • 1Email author
Journal of Neuroinflammation201310:883

  • Received: 22 July 2013
  • Accepted: 9 September 2013
  • Published:



Growing evidence suggests that alterations of the inflammatory/immune system contribute to the pathogenesis of depression. Indeed, depressed patients exhibit increased levels of inflammatory markers in both the periphery and the brain, and high comorbidity exists between major depression and diseases associated with inflammatory alterations. In order to characterize the link between depression and inflammation, we aimed to investigate whether an altered inflammatory system is present in a genetic model of vulnerability for depression, namely rats with partial or total deletion of the serotonin transporter (SERT) gene.


Wild-type, heterozygous and homozygous SERT rats were analyzed under basal condition or following a challenge with an acute injection of lipopolysaccharide (LPS) and killed 24 h or 5 days later.


We found that SERT mutant rats show altered cytokine expression in the dorsal and ventral hippocampus at basal conditions, and they also display an exacerbated cytokine response to the LPS challenge. Moreover, mutant rats exhibit differences in the expression of markers for microglia activation.


Based on these data, we suggest that basal or functional alterations of immune/inflammatory systems might contribute to the phenotype of SERT rats and to their heightened susceptibility to depressive-like behavior.


  • Inflammation
  • Lipopolysaccharide (LPS)
  • Cytokines
  • Microglia
  • Animal model


Major depressive disorder (MDD) is a leading cause of disability in the world supposedly originating from the interaction between a background of genetic vulnerability and adverse environmental factors. Compelling evidence also suggests that inflammation may contribute to specific dysfunctions associated with depression [1, 2]. Accordingly, depression shows elevated comorbidity with immune-related diseases such as cancer, cardiovascular and neurodegenerative diseases that are characterized by the presence of inflammatory alterations [3, 4]. In addition, depressed patients exhibit all the cardinal features of inflammation [5]. Indeed, elevated blood levels of the proinflammatory cytokines, including interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α, are commonly found in depressive subjects [69]. It has also been shown that depressed suicidal attempters display elevated levels of IL-6 in the cerebrospinal fluid [10]. Moreover, it has been demonstrated that IL-6 is related to the stress-induced development of depression-like behaviors in mice [11].

Furthermore, the endotoxin lipopolysaccharide (LPS), a proinflammatory agent, can trigger the development of depressive symptoms in humans as well as depressive-related behavior in rodents [1, 1214]. In line with this, patients treated with interferons and interleukins often develop depression [15]. This evidence suggests that immune-inflammatory signals may represent an ‘environmental’ condition relevant for the etiology of mood disorders, which may also unmask a latent genetic vulnerability.

In this respect, one of the most extensively investigated susceptibility genes in depression encodes for the serotonin transporter (5-HTT or SERT), which is responsible for the re-uptake of serotonin into the presynaptic terminal [16]. The 5-HTT gene exists in two major allelic variants, a long (L) form and a short (S) form. It has been demonstrated that the S variant leads to reduced expression of the transporter [17] and might enhance the sensitivity to the pro-depressive effects of stressful life events in rhesus monkeys [18] as well as in humans [19, 20]. Furthermore, SERT knockout mice [2123], as well as SERT mutant rats [24], show depression and anxiety-related behaviors, as well as impaired neuronal plasticity [2527], supporting the possibility that altered function of SERT may be associated with increased risk of mood disorders [28]. Interestingly, it has been recently shown that the short variant of SERT is also associated with higher risk of developing depression in patients following INF-α treatment [29].

Based on these observations, the purpose of the present study was twofold. First, we established whether partial or total deletion of the SERT gene is associated with altered expression of inflammatory markers in basal conditions. Next, in order to establish whether genetic susceptibility to depression is associated with significant changes in the inflammatory/immune system, we investigated whether SERT heterozygous rats show altered responsiveness to an inflammatory challenge with LPS. We chose SERT+/− animals since the partial SERT deletion better mimics the condition of humans carrying the short variant of the 5-HTTLPR, which has been associated with enhanced susceptibility to environmental adversities [30]. The higher validity of SERT heterozygous models has already been discussed [31, 32], and the behavioral vulnerability of SERT heterozygous animals has been previously demonstrated for mice [21, 33].


General reagents were purchased from Sigma-Aldrich (Milan, Italy), and molecular biology reagents were obtained from Applied Biosystem Italia (Monza, Italy), Eurofins MWG-Operon (Ebersberg, Germany) and Bio-Rad Laboratories S.r.l. (Segrate, Italy). Lipopolysaccharide (from Escherichia coli 026:B6 ≥10,000 eu/mg) was purchased from Sigma-Aldrich (code L8274).

Animals and experimental paradigm

Serotonin transporter knockout rats (Slc6a41Hubr) were generated in a Wistar background by N-ethyl-N-nitrosurea (ENU)-induced mutagenesis [34]. Experimental animals were derived from crossing heterozygous SERT knockout rats that were out crossed for at least ten generations with wild-type Wistar rats obtained from Harlan Laboratories. All subjects were bred and reared in the Central Animal Laboratory of the University of Nijmegen. After weaning at the age of 21 days, ear cuts were taken for genotyping. In all experiments, adult male SERT+/+(WT), SERT+/− and SERT−/− rats were used. Animals were housed in groups of four per cage under standard conditions (12-h light/dark cycle with food and water ad libitum) and were exposed to daily handling for 1 week before any treatment.

Rats were randomly divided into two experimental groups: control (39 rats) and treated animals (40 rats); the first group received saline, whereas the second one was treated with a single injection of lipopolysaccharide (250 μg/Kg, i.p.). They were killed 1 or 5 days later. Our analyses were carried out in the ventral and dorsal hippocampus, which were rapidly dissected, frozen on dry ice and stored at −80°C for molecular analyses.

All experiments were approved by the Committee for Animal Experiments of the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, and all efforts were made to minimize animal suffering and to reduce the number of animals used in accordance with the Guidelines laid down by the European Communities Council Directive of 24 November 1986 (86/609/EEC).

Protein analysis of plasma inflammatory mediators

Samples of blood from each rat were collected in heparinized tubes. Plasma was separated by centrifugation (5,000 rpm for 10 min at 4°C), and interleukin (IL)-6, tumor necrosis factor (TNF)-α, cytokine-induced neutrophil chemoattractant (CINC)-1, CINC-3 and macrophage inflammatory protein (MIP)-1α protein levels were quantified using a Rat Cytokine Array kit (R&D Systems, Inc.) according to the manufacturer’s instructions. Briefly, plasma was diluted and mixed with a cocktail of biotinylated detection antibodies. The sample/antibody mixture was then incubated with the rat cytokine array membrane where capture and control antibodies have been spotted. Any cytokine/detection antibody complex present was bound by its cognate immobilized capture antibody on the membrane. Following a wash to remove unbound material, streptavidin-HRP and chemiluminescent detection reagents were applied and a signal was produced at each spot corresponding to the amount of cytokine bound. Protein levels were calculated by measuring the optical density of the autoradiographic bands using Quantity One software (Bio-Rad Laboratories). To ensure that autoradiographic bands were in the linear range of intensity, different exposure times were used.

RNA preparation and gene expression analyses

For gene expression analysis, total RNA was isolated from the different brain regions by single-step guanidinium isothiocyanate/phenol extraction using the PureZol RNA isolation reagent (Bio-Rad Laboratories S.r.l.; Segrate, Italy) according to the manufacturer’s instructions and quantified by spectrophotometric analysis. The samples were then processed for real-time polymerase chain reaction (PCR) as previously reported [35] to assess levels of interleukin 1β (IL-1β) interleukin-6 (IL-6), integrin alpha M (cluster of differentiation molecule CD11b), chemokine (C-X3-C motif) ligand 1 (CX3CL1; fractalkine) and integrin-associated protein (CD47).

Briefly, an aliquot of each sample was treated with DNase to avoid DNA contamination and subsequently analyzed by the TaqMan qRT-PCR instrument (CFX384 real-time system, Bio-Rad Laboratories S.r.l.) using the iScript one-step RT-PCR kit for probes (Bio-Rad Laboratories S.r.l.). Samples were run in 384-well format in triplicate as multiplexed reactions with a normalizing internal control (β-actin). Thermal cycling was initiated with incubation at 50°C for 10 min (RNA retrotranscription) and then at 95°C for 5 min (TaqMan polymerase activation). After this initial step, 39 cycles of PCR were performed. Each PCR cycle consisted of heating the samples at 95°C for 10 s to enable the melting process, and then for 30 s at 60°C for the annealing and extension reactions. A comparative cycle threshold (Ct) method was used to calculate the relative target gene expression. Probe and primer sequences used were purchased from Applied Biosystem Italia and Eurofins MWG-Operon.

Statistical analyses

The effect of the genotype on gene expression was analyzed with a one-way analysis of variance (ANOVA), followed by Fisher’s protected least significant difference (Fisher PLSD), whereas the effect of the LPS was analyzed with a two-way ANOVA with genotype (WT vs. SERT+/− rats) and treatment (Sal vs. LPS) as independent factors and mRNA levels as dependent variable. When appropriate, further differences were analyzed by single contrast post hoc test (SCPHT). Significance for all tests was assumed at P < 0.05. Data are presented as means ± standard error (SEM). For graphic clarity, results are presented as mean percent of WT rats (basal effect analysis) and WT or SERT+/− rats treated with saline (LPS effect analysis).


We first analyzed different markers of the immune system at the peripheral level of SERT+/− and SERT−/− animals. Specifically, we measured the protein level of two cytokines, IL-6 and TNF-α and CINC-1, CINC-3 and MIP-1α, which belong to the family of chemokines. As shown in Table 1, all these markers were strongly upregulated in the plasma of SERT−/− rats, whereas we did not find any change in SERT heterozygous animals.
Table 1

Protein analysis of inflammatory mediators in the plasma of SERT mutant rats


SERT +/−

SERT −/−
















The table shows the changes of interleukin 6 (IL-6), tumor necrosis factors (TNF-α), cytokine-induced neutrophil chemoattractant 1 (CINC-1), cytokine-induced neutrophil chemoattractant 3 (CINC-3) and macrophage inflammatory protein (MIP-1α) found in SERT mutant as compared to wild-type animals. =, no change; +, 5- to 10-fold increase; ++ 20- to 30-fold increase; +++ more than 30-fold increase.

On these bases, we decided to analyze the expression levels of inflammatory markers in the hippocampus of mutant rats under resting conditions or following an acute challenge with LPS. We chose to investigate this brain area because it is highly relevant for depression and it is also vulnerable to environmental challenges [3638]. Moreover, we decided to compare the ventral and dorsal part of the hippocampus since the two subregions subserve different functions. In particular, the dorsal part (DH) has been linked to cognition, whereas the ventral portion (VH) has been associated with emotion and stress responses [39].

IL-1β expression

We first measured IL-1β mRNA and, as shown in Figure 1, we found that under basal conditions the expression of IL-1β was significantly increased in the dorsal hippocampus (A) of SERT+/− and SERT−/− animals (+55%, P < 0.001; +37%, P < 0.05 respectively), whereas, in the ventral hippocampus, (B) the cytokine mRNA levels were increased only in rats with partial deletion of the gene (+68%, P < 0.01). Next, we investigated the responsiveness of SERT+/− rats to a challenge with the proinflammatory agent LPS. The analyses were carried out only in SERT+/− rats, which more closely mimic the genetic vulnerability associated with patients carrying the S variant of the 5-HTT gene. In the dorsal hippocampus (Figure 1C), we found that LPS produced similar changes in both genotypes. Indeed, the mRNA levels for IL-1β were significantly increased 1 day after LPS injection in WT (+634%, P < 0.01) as well as in SERT+/− rats (+513%, P < 0.05), but not after 5 days when the cytokine expression levels had returned to control levels. Conversely, in the ventral hippocampus (Figure 1D), LPS injection produced larger changes in SERT+/− rats since IL-1β upregulation at 24 h was more pronounced in mutant animals (+964% vs. +370% in WT rats) and also persisted up to 5 days after the proinflammatory challenge (+156%, P < 0.05) when the cytokine expression had returned to control levels in wild-type rats.
Figure 1
Figure 1

Analysis of interleukin (IL)-1β gene expression in the hippocampus of SERT mutant rats. Basal expression of IL-1β mRNA levels were measured in dorsal (A) and ventral (B) hippocampus of mutant rats. The data, expressed as percentage of SERT+/+ (wild-type) animals (set at 100%), are the mean ± SEM of at least five independent determinations. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. SERT+/+ (one-way ANOVA with SCPHT). The expression of IL-1β was also investigated in dorsal (C) and ventral (D) hippocampus following an acute LPS challenge, the animals being killed 1 or 5 days after the immune challenge. The data are expressed as percentage of the respective saline-injected counterpart (set at 100%, dashed line) and represent the mean ± SEM of at least five independent determinations. #P < 0.05, ##P < 0.01, ###P < 0.001 vs. control (one-way ANOVA with SCPHT).

IL-6 expression

Unlike what we observed for IL-1β, the mRNA levels of IL-6 (Figure 2) were not significantly altered under basal conditions in the dorsal (A) or ventral hippocampus (B) of SERT mutant rats. However, we found that the SERT genotype had a significant effect on the modulation of IL-6 gene expression after LPS challenge. In the dorsal hippocampus (Figure 2C), 24 h after LPS injection, IL-6 mRNA levels were significantly increased in SERT+/− (+136%, P < 0.001) but not wild-type animals (+58%, P = 0.067), whereas the cytokine expression was back to control levels in both genotypes 5 days post-LPS. A similar profile was found in the ventral hippocampus (Figure 2D), since IL-6 expression was upregulated 24 h post LPS administration in SERT+/− (+58%, P < 0.01) but not in WT rats (−11%, P = 0.565). Also in this brain region, no significant changes of IL-6 mRNA levels were found 5 days after LPS challenge in both genotypes.
Figure 2
Figure 2

Analysis of interleukin (IL)-6 gene expression in the hippocampus of SERT mutant rats. Basal interleukin (IL)-6 gene expression is not altered in dorsal (A) or ventral (B) hippocampus of mutant rats. The data, expressed as percentage of SERT+/+ (wild-type) animals (set at 100%), are the mean ± SEM of at least five independent determinations. The expression of IL-6 is upregulated in both dorsal (C) and ventral (D) hippocampus only in SERT+/− animals 1 day after an lipopolysaccharide (LPS) challenge. The data are expressed as percentage of the respective saline-injected counterpart (set at 100%, dashed line) and represent the mean ± SEM of at least five independent determinations. ##P < 0.01, ###P < 0.001 vs. control (one-way ANOVA with SCPHT).

CD11b expression

Besides cytokine production, another important aspect of the inflammatory response is microglia activation [40]. In order to evaluate if the basal activity of microglia was altered as a consequence of SERT gene deletion, we assessed the expression of CD11b, a marker for this cellular phenotype [41]. As shown in Figure 3A, we found that the basal expression of CD11b was significantly higher in dorsal hippocampus of SERT+/− (+56%, P < 0.05) but not in SERT−/− rats. A similar change was also observed in the ventral hippocampus (Figure 3B) where the expression of the microglial marker was significantly upregulated under basal conditions in SERT+/− (+120%, P < 0.01) as well as in SERT−/− rats (+173%, P < 0.001).
Figure 3
Figure 3

Analysis of integrin alpha M (CD11b) gene expression in the hippocampus of SERT mutant rats. Basal CD11b gene expression is altered in dorsal (A) and ventral (B) hippocampus of mutant rats. The data, expressed as percentage of SERT+/+ animals (set at 100%), are the mean ± SEM of at least five independent determinations. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. SERT+/+ (one-way ANOVA with SCPHT). The expression of CD11b is upregulated in dorsal (C) and ventral (D) hippocampus of WT or SERT+/− animals 1 or 5 days after an LPS challenge. The data are expressed as percentage of the respective saline-injected counterpart (set at 100%, dashed line) and represent the mean ± SEM of at least five independent determinations. ##P < 0.01, ###P < 0.001 vs. control (one-way ANOVA with SCPHT).

Next, we examined CD11b mRNA levels following the acute LPS challenge. In the dorsal hippocampus (Figure 3C), the mRNA levels of CD11b were significantly increased 1 day after LPS treatment in WT (+312%, P < 0.001) as well as in SERT+/− rats (+274%, P < 0.001), while its expression returned to basal levels in both genotypes 5 days post-LPS. In the ventral hippocampus (Figure 3D), we found a significant increase of CD11b mRNA levels 24 h after LPS injection in WT (+436%, P < 0.001) and SERT+/− rats (+332%, P < 0.001). However, 5 days after LPS challenge the mRNA levels of CD11b were upregulated in WT rats (140%, P < 0.001), but they had returned to baseline in SERT+/− rats.

CX3CL1 and CD47 expression

In order to gain further insight into the changes of microglial function, we investigated the glia-neuron cross-talk. Indeed, microglial function may be controlled through signals that keep it in a resting state or that may favor its activation [42]. In this respect, the interactions between fractalkine (CX3CL1) and CD47 with their receptors play a crucial role in maintaining microglia in a resting state [43]. Therefore, we analyzed the expression of CX3CL1 and CD47 in the dorsal and ventral hippocampus of SERT+/− and wild-type animals.

As shown in Figure 4A, the expression of CX3CL1 was not altered in the dorsal hippocampus of SERT+/− rats under basal conditions, while its mRNA levels were increased in the ventral subregion of mutant rats (+36%, P < 0.001).
Figure 4
Figure 4

Analysis of chemokine ligand 1 (CX3CL1) gene expression in the hippocampus of SERT mutant rats. Basal CX3CL1 gene expression is altered in the ventral hippocampus of mutant rats (B) but not in the dorsal hippocampus (A). The data, expressed as percentage of SERT+/+ animals (set at 100%), are the mean ± SEM of at least five independent determinations. ***P < 0.001 vs. SERT+/+ (one-way ANOVA with SCPHT). The expression of CX3CL1 is modulated in dorsal (C) and ventral (D) hippocampus of WT or SERT+/− animals 1 or 5 days after an LPS challenge. The data are expressed as percentage of the respective saline-injected counterpart (set at 100%, dashed line) and represent the mean ± SEM of at least five independent determinations. #P < 0.5, ###P < 0.001 vs. control (one-way ANOVA with SCPHT).

When considering the inflammatory challenge, CX3CL1 mRNA levels were not altered in the dorsal hippocampus of WT rats 24 h after LPS treatment (Figure 4C), while they were significantly increased in SERT+/− animals (+42%, P < 0.001). Conversely, 5 days after the LPS challenge, the expression of CX3CL1 was significantly reduced in both genotypes (WT: -19%, P < 0.05; SERT+/−: -20%, P < 0.05). In the ventral hippocampus (Figure 4D), the mRNA levels of CX3CL1 were upregulated 1 day after LPS injection in WT rats (+144%, P < 0.001), but not in SERT+/− animals, whereas no significant changes were observed 5 days post-LPS challenge.

Conversely, as shown in Figure 5, basal expression of CD47 was reduced in the dorsal hippocampus of SERT+/− rats (−34%, P < 0.01), while it was increased in the ventral hippocampus (+144%, P < 0.001). Following LPS challenge, the expression of CD47 was not altered in the dorsal hippocampus of WT rats 24 h post-injection, and it was reduced 5 days after (−23%, P < 0.05), (Figure 5C). Conversely, the expression of CD47 was decreased at 24 h post-LPS in SERT+/− animals (−30%, P < 0.05), but was significantly upregulated 5 days post-LPS injection (+30%, P < 0.05). In the ventral hippocampus (Figure 5D), the mRNA levels of CD47 were upregulated 1 day after LPS administration in WT rats (+99%, P < 0.001) but not in SERT+/− animals. On the contrary, 5 days after the inflammatory challenge the expression of the microglial marker had returned to control values in WT rats, while being significantly increased in SERT mutant rats (+29%, P < 0.05).
Figure 5
Figure 5

Analysis of integrin-associated protein (CD47) gene expression in the hippocampus of SERT mutant rats. Basal CD47 mRNA levels are decreased in the dorsal hippocampus (A) of SERT+/− rats, while they are increased in the ventral hippocampus (B). The data, expressed as percentage of SERT+/+ animals (set at 100%), are the mean ± SEM of at least five independent determinations. **P < 0.01 and ***P < 0.001 vs. SERT+/+ (one-way ANOVA with SCPHT). The expression of CD47 is modulated in dorsal (C) and ventral (D) hippocampus of WT or SERT+/− animals 1 or 5 days after an LPS challenge. The data are expressed as percentage of the respective saline-injected counterpart (set at 100%, dashed line) and represent the mean ± SEM of at least five independent determinations. #P < 0.05, ###P < 0.001 vs. control (one-way ANOVA with SCPHT).


Our results suggest that genetic deletion of the serotonin transporter in rats is associated with alterations of immune/inflammatory players, such as proinflammatory cytokines and markers of microglia activation, under basal conditions or following an immune challenge. These results support the idea of a close and reciprocal modulation between a gene strongly associated with depression and systems involved in the immune response, in line with the idea that inflammation represents an important environmental factor for depression susceptibility [1, 44, 45]. Indeed, we demonstrate that animals with partial or total deletion of the SERT gene have, under basal conditions, enhanced levels of circulating immune proteins as well as increased expression of IL-1β in dorsal and ventral hippocampus. In this respect, it is interesting to notice that major changes occurred in heterozygous animals, which mimic more closely the human situation of individuals carrying the short (S) variant of the SERT gene that is associated with enhanced vulnerability to depressive disorders [19, 20]. Besides this, Su and colleagues have demonstrated that in S-carrier subjects depressive symptoms are associated with elevated plasma levels of IL-6 [46]. Moreover, healthy SS carriers of the serotonin transporter show, when compared to LL carriers, a proinflammatory phenotype, measured as the ratio between IL-6 and IL-10, under resting conditions as well as following an acute stress [47]. These data are in good agreement with the results of our study, also in respect to the responsiveness to an immune challenge. In particular, while cytokine mRNA levels are similarly increased in the dorsal hippocampus of all genotypes, the response to LPS was exacerbated in the ventral hippocampus of SERT+/− rats, where the cytokine upregulation was not only quantitatively larger but also lasted up to 5 days after the inflammatory challenge. The anatomical specificity is in line with the potential role of these changes for depression considering that the ventral subregion of the hippocampus is primarily involved in emotional responses and stress regulation [48].

One key element of the inflammatory response is the activation and modulation of microglia [40]. These cerebral immune cells are normally present in the healthy brain where they actively survey the system and may rapidly respond to any microenvironment alteration [49]. To substantiate the phenotype of SERT mutant rats, we found increased mRNA levels of CD11b in the ventral and dorsal hippocampus. In particular, SERT+/− rats displayed more obvious alterations, suggesting once again that heterozygous rats are more sensitive to an LPS challenge. Indeed, we observed a genotype-dependent increase in CD11b: after 24 h from LPS administration there was no difference, whereas after 5 days microglia was still activated in wild-type but not in SERT+/− animals. The interpretation of these results is not straightforward, since the mechanisms underlying microglia activation and its functional consequences are not completely understood. Indeed, microglia is considered to function as a double-edged sword since its response is not necessarily neurotoxic, but may be useful to control and clear damage resulting from challenging conditions [42]. In line with these considerations, our results suggest that SERT mutant rats show activated microglia under basal conditions, which may eventually be associated with a chronic inflammatory state, also suggested by increased expression of proinflammatory cytokines. On the other hand, the microglial response to the inflammatory challenge is largely similar in SERT wild-type and mutant rats, suggesting that the intensity of the challenge may not be adequate for discriminating between the two cohorts.

Microglia is maintained in a resting state through neuron-derived signals including CX3CL1 and CD47, which act on their respective receptors CX3CR1 and CD172A expressed by microglia [42, 50, 51]. However, according to our data, the activation of microglia observed in mutant rats under basal condition cannot be explained by changes in the expression of CX3CL1 and CD47, as their mRNA levels are even higher in the ventral hippocampus of SERT+/− rats. We may speculate that the basal upregulation of these genes may represent a compensatory mechanism aimed at limiting the microglial activation observed in SERT mutant rats under basal conditions. In line with this interpretation, 24 h after the LPS challenge CX3CL1 and CD47 mRNA levels were markedly increased in wild-type animals but not in mutant rats, further suggesting a dysregulation of the mechanisms responsible for the control of microglial function and activation.

Multiple molecular mechanisms may be involved in the differential inflammatory response observed after LPS challenge in SERT mutant rats. For example, it is known that LPS can activate and recruit Toll-like receptors (TLRs), especially TLR4, which appear important in mood-related disorders [52]. However, since hippocampal TLR4 gene expression is not altered in SERT mutant rats (data not shown), other mechanism may be responsible for heightened responsiveness to LPS challenge of SERT+/− rats.

In conclusion, our results demonstrate that the inflammatory/immune system is altered in rats with genetic alterations of the serotonin transporter. Moreover, these animals show a different response to an inflammatory challenge, suggesting that some of the mechanisms that regulate these systems can be compromised, thus rendering the hippocampus more susceptible to the adverse influence of inflammatory mediators. Since depression vulnerability can be associated with increased inflammation, we suggest that the alterations of the immune system observed in animals with a deletion of the SERT gene may contribute to their pathologic phenotype. Furthermore, considering that depressed patients with higher levels of cytokines, as well as individuals carrying the S variant of the 5-HTTLPR polymorphism, are less responsive to antidepressant treatment [53, 54], we may speculate that alterations of the immune/inflammatory system in depressed individuals may not only contribute to the pathologic phenotype, but also represent an important component for the response to pharmacological intervention.



Chemokine (C-X3-C Motif) ligand 1 or fractalkine


Chemokine (C-X3-C Motif) receptor 1


Cytokine-induced neutrophil chemoattractant


Dorsal hippocampus


Integrin alpha M or cluster of differentiation


Integrin-associated protein








Macrophage inflammatory protein


Polymerase chain reaction


Serotonin transporter




Tumor necrosis factor


Ventral hippocampus





We are grateful to Juliet Richetto for language editing. Special thanks to Antonieke Middleman, Marina Catalano and Paola Mara Rossi for contributing to part of this research.

This research was supported by grants to M.A. Riva from Regione Lombardia (Markdep) and from the Ministry of University and Research (protocol no. 20107MSMA4). This work was also funded by The Netherlands Organisation for Scientific Research (NWO), grant no. 86410003, awarded to J. Homberg. NWO had no further role in the design of the study, in the collection, analysis and interpretation of data, in the writing of the report or in the decision to submit the paper for publication.

Authors’ Affiliations

Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy
Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, University of Catania, Catania, Italy
Donders Institute for Brain Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milan, Italy


  1. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46–56.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Zunszain PA, Hepgul N, Pariante CM: Inflammation and depression. Curr Top Behav Neurosci 2013, 14:135–151.View ArticlePubMedGoogle Scholar
  3. Benton T, Staab J, Evans DL: Medical co-morbidity in depressive disorders. Ann Clin Psychiatry 2007, 19:289–303.View ArticlePubMedGoogle Scholar
  4. Anisman H, Merali Z, Hayley S: Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008, 85:1–74.View ArticlePubMedGoogle Scholar
  5. Miller AH: Depression and immunity: a role for T cells? Brain Behav Immun 2010, 24:1–8.View ArticlePubMedGoogle Scholar
  6. Connor TJ, Leonard BE: Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998, 62:583–606.View ArticlePubMedGoogle Scholar
  7. Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999, 461:25–46.View ArticlePubMedGoogle Scholar
  8. Hestad KA, Tonseth S, Stoen CD, Ueland T, Aukrust P: Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003, 19:183–188.View ArticlePubMedGoogle Scholar
  9. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O’Brien JT: Increase in interleukin-1beta in late-life depression. Am J Psychiatry 2005, 162:175–177.View ArticlePubMedGoogle Scholar
  10. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, Hansson O, Bjorkqvist M, Traskman-Bendz L, Brundin L: Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009, 66:287–292.View ArticlePubMedGoogle Scholar
  11. Chourbaji S, Urani A, Inta I, Sanchis-Segura C, Brandwein C, Zink M, Schwaninger M, Gass P: IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol Dis 2006, 23:587–594.View ArticlePubMedGoogle Scholar
  12. Yirmiya R: Endotoxin produces a depressive-like episode in rats. Brain Res 1996, 711:163–174.View ArticlePubMedGoogle Scholar
  13. Pucak ML, Kaplin AI: Unkind cytokines: current evidence for the potential role of cytokines in immune-mediated depression. Int Rev Psychiatry 2005, 17:477–483.View ArticlePubMedGoogle Scholar
  14. Frenois F, Moreau M, O’Connor J, Lawson M, Micon C, Lestage J, Kelley KW, Dantzer R, Castanon N: Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516–531.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Capuron L, Ravaud A, Dantzer R: Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000, 18:2143–2151.PubMedGoogle Scholar
  16. Blakely RD, De Felice LJ, Hartzell HC: Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 1994, 196:263–281.PubMedGoogle Scholar
  17. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527–1531.View ArticlePubMedGoogle Scholar
  18. Bennett AJ, Lesch KP, Heils A, Long JC, Lorenz JG, Shoaf SE, Champoux M, Suomi SJ, Linnoila MV, Higley JD: Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol Psychiatry 2002, 7:118–122.View ArticlePubMedGoogle Scholar
  19. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386–389.View ArticlePubMedGoogle Scholar
  20. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE: Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010, 167:509–527.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Holmes A, Lit Q, Murphy DL, Gold E, Crawley JN: Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav 2003, 2:365–380.View ArticlePubMedGoogle Scholar
  22. Lira A, Zhou M, Castanon N, Ansorge MS, Gordon JA, Francis JH, Bradley-Moore M, Lira J, Underwood MD, Arango V, et al.: Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry 2003, 54:960–971.View ArticlePubMedGoogle Scholar
  23. Urani A, Chourbaji S, Gass P: Mutant mouse models of depression: candidate genes and current mouse lines. Neurosci Biobehav Rev 2005, 29:805–828.View ArticlePubMedGoogle Scholar
  24. Olivier JD, Van Der Hart MG, Van Swelm RP, Dederen PJ, Homberg JR, Cremers T, Deen PM, Cuppen E, Cools AR, Ellenbroek BA: A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders. Neuroscience 2008, 152:573–584.View ArticlePubMedGoogle Scholar
  25. Calabrese F, Molteni R, Cattaneo A, Macchi F, Racagni G, Gennarelli M, Ellenbroek BA, Riva MA: Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. Mol Pharmacol 2010, 77:846–853.View ArticlePubMedGoogle Scholar
  26. Calabrese F, Luoni A, Guidotti G, Racagni G, Fumagalli F, Riva MA: Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid. Psychopharmacology (Berl) 2013, 226:101–112.View ArticleGoogle Scholar
  27. Molteni R, Cattaneo A, Calabrese F, Macchi F, Olivier JD, Racagni G, Ellenbroek BA, Gennarelli M, Riva MA: Reduced function of the serotonin transporter is associated with decreased expression of BDNF in rodents as well as in humans. Neurobiol Dis 2010, 37:747–755.View ArticlePubMedGoogle Scholar
  28. Gardier AM: Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor. Behav Pharmacol 2009, 20:18–32.View ArticlePubMedGoogle Scholar
  29. Lotrich FE: Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci 2009, 11:417–425.PubMedPubMed CentralGoogle Scholar
  30. Karg K, Burmeister M, Shedden K, Sen S: The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 2011, 68:444–454.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Kalueff AV, Ren-Patterson RF, Murphy DL: The developing use of heterozygous mutant mouse models in brain monoamine transporter research. Trends Pharmacol Sci 2007, 28:122–127.View ArticlePubMedGoogle Scholar
  32. Homberg JR, van den Hove DL: The serotonin transporter gene and functional and pathological adaptation to environmental variation across the life span. Prog Neurobiol 2012, 99:117–127.View ArticlePubMedGoogle Scholar
  33. Carola V, Frazzetto G, Pascucci T, Audero E, Puglisi-Allegra S, Cabib S, Lesch KP, Gross C: Identifying molecular substrates in a mouse model of the serotonin transporter x environment risk factor for anxiety and depression. Biol Psychiatry 2008, 63:840–846.View ArticlePubMedGoogle Scholar
  34. Smits BM, Mudde JB, van de-Belt J, Verheul M, Olivier J, Homberg J, Guryev V, Cools AR, Ellenbroek BA, Plasterk RH, Cuppen E: Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesis. Pharmacogenet Genomics 2006, 16:159–169.PubMedGoogle Scholar
  35. Molteni R, Macchi F, Zecchillo C, Dell’agli M, Colombo E, Calabrese F, Guidotti G, Racagni G, Riva MA: Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine. Eur Neuropsychopharmacol 2013. Epub ahead of printGoogle Scholar
  36. Chourbaji S, Gass P: Glucocorticoid receptor transgenic mice as models for depression. Brain Res Rev 2008, 57:554–560.View ArticlePubMedGoogle Scholar
  37. Chourbaji S, Hortnagl H, Molteni R, Riva MA, Gass P, Hellweg R: The impact of environmental enrichment on sex-specific neurochemical circuitries - effects on brain-derived neurotrophic factor and the serotonergic system. Neuroscience 2012, 220:267–276.View ArticlePubMedGoogle Scholar
  38. Fumagalli F, Caffino L, Vogt MA, Frasca A, Racagni G, Sprengel R, Gass P, Riva MA: AMPA GluR-A receptor subunit mediates hippocampal responsiveness in mice exposed to stress. Hippocampus 2011, 21:1028–1035.PubMedGoogle Scholar
  39. Fanselow MS, Dong HW: Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010, 65:7–19.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Saijo K, Glass CK: Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 2011, 11:775–787.View ArticlePubMedGoogle Scholar
  41. Perego C, Fumagalli S, De Simoni MG: Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J Neuroinflammation 2011, 8:174.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Biber K, Neumann H, Inoue K, Boddeke HW: Neuronal ‘On’ and ‘Off’ signals control microglia. Trends Neurosci 2007, 30:596–602.View ArticlePubMedGoogle Scholar
  43. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, et al.: Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 1998, 95:10896–10901.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Lotrich FE, El-Gabalawy H, Guenther LC, Ware CF: The role of inflammation in the pathophysiology of depression: different treatments and their effects. J Rheumatol Suppl 2011, 88:48–54.View ArticlePubMedGoogle Scholar
  45. Raedler TJ: Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011, 24:519–525.PubMedGoogle Scholar
  46. Su S, Zhao J, Bremner JD, Miller AH, Tang W, Bouzyk M, Snieder H, Novik O, Afzal N, Goldberg J, Vaccarino V: Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet 2009, 2:614–620.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Fredericks CA, Drabant EM, Edge MD, Tillie JM, Hallmayer J, Ramel W, Kuo JR, Mackey S, Gross JJ, Dhabhar FS: Healthy young women with serotonin transporter SS polymorphism show a pro-inflammatory bias under resting and stress conditions. Brain Behav Immun 2010, 24:350–357.View ArticlePubMedGoogle Scholar
  48. Felice D, O’Leary OF, Pizzo RC, Cryan JF: Blockade of the GABA(B) receptor increases neurogenesis in the ventral but not dorsal adult hippocampus: Relevance to antidepressant action. Neuropharmacology 2012, 63:1380–1388.View ArticlePubMedGoogle Scholar
  49. Janssen DG, Caniato RN, Verster JC, Baune BT: A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010, 25:201–215.View ArticlePubMedGoogle Scholar
  50. Hanisch UK, Kettenmann H: Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387–1394.View ArticlePubMedGoogle Scholar
  51. Neher JJ, Neniskyte U, Brown GC: Primary phagocytosis of neurons by inflamed microglia: potential roles in neurodegeneration. Front Pharmacol 2012, 3:27.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Garate I, Garcia-Bueno B, Madrigal JL, Bravo L, Berrocoso E, Caso JR, Mico JA, Leza JC: Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. J Neuroinflammation 2011, 8:151.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Serretti A, Kato M, De-Ronchi D, Kinoshita T: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007, 12:247–257.PubMedGoogle Scholar
  54. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J: Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:722–726.View ArticlePubMedGoogle Scholar


© Macchi et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.